Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

By Charles M. Balch, A. Buzaid, S. Soong, Michael B. Atkins, N. Cascinelli, D. Coit, Irvin D. Fleming, J. Gershenwald, Alan N. Houghton, John M. Kirkwood and 8 more. Journal of Clinical Oncology, 2001

2,696 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/e7658689321ee471bf4ec71332a9728daa429f4c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Scott W. Lowe
2. Qi-Yan Dou

In Molecular Biology

1. M. Soengas
2. Scott W. Lowe
3. J. Campisi

In Oncology

1. P. Heng
2. Hao Chen
3. Lequan Yu
4. M. Soengas
5. K. Flaherty
6. Scott W. Lowe
7. Georgina V. Long
8. Balázs Harangi

Citations in the corpus

• Automated Melanoma Recognition in Dermoscopy Images via Very Deep Residual Networks (2017, background): “Fortunately, if melanoma is detected in its early stages and treated properly, the survival rate is very high [3], [4].”
• Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. (2012, background): “pendent principally on tumor thickness and to a lesser extent on other features of the primary tumor, such as mitotic rate, ulcerative state, and anatomic site, as well as patient characteristics, such as age and sex.(3,4) In recent times, additional prognostic information has been obtained by senti”
• Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 (2004, methodology): “Cancer stage was gathered according to the American Joint Committee on Cancer (41) (see Table I).”
• Apoptosis and melanoma chemoresistance (2003, background): “Complete surgical excision of the primary tumor has over a 95% success rate at stages I/II and it can even substantially extend the long-term survival of patients with lymph node infiltrations (stage III) (Balch et al., 2001).”
• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, background): “Several large series have demonstrated that patients with clinically occult regional node disease have better survival than those with clinically evident disease.(52,60-62) This was also evident in the AJCC MSS curves according to N category and N subcategory, as shown in Figure 3.”
• NRAS Mutation Status is an Independent Prognostic Factor in Metastatic Melanoma (2011, neutral): “6 [0-517] 27.”
• Increasing burden of melanoma in the United States (2009, positive): “Melanoma in the elderly may have a different biology and altered host immune response, both of which could contribute to increased incidence and mortality (Balch et al., 2001b).”
• Final version of 2009 AJCC melanoma staging and classification. (2009, methodology): “© 2009 by American Society of Clinical Oncology INTRODUCTION The current melanoma staging system was substantially revised in 2001 for the sixth edition of the Cancer Staging Manual, on the basis of an analysis of 17,600 patients in the American Joint Committee on Cancer (AJCC) Melanoma Staging Data”
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, methodology): “The BRIM8 study analysed vemurafenib monotherapy versus a placebo in stage IIC and stage III (AJCC 7th edition [43]) melanoma after complete surgical resection.”